Twist Bioscience has launched Twist Express Screening Antibodies, a high-throughput, cell-free service that delivers purified full-length IgG with surface plasmon resonance (SPR) binding data. The service turns customer-supplied variable region sequences into purified IgG, scFv-Fc, or VHH-Fc antibodies. It uses LenioBio's ALiCE eukaryotic expression system. Quantities range from 5 μg to 20 μg, and turnaround starts at five days. Chief executive officer Emily M. Leproust said AI-guided discovery is widening the range of candidates, making fast experimental data critical. Researchers can screen broad candidate sets, then move selected antibodies into Twist's HEK293 or CHO expression and characterisation workflows.

Twist Bioscience launches Express Screening Antibodies, expanding production and characterization portfolio. The workflow incorporates cell-free protein expression powered by LenioBio's eukaryotic expression system. October 28, 2026 Content Marketing Editor Editor's Take: This offering boosts Twist's broader antibody portfolio. Twist Bioscience introduced Twist Express Screening Antibodies, a high-throughput, cell-free offering expanding Twist's antibody production and characterization portfolio. According to the company, Twist Express Screening Antibodies speed the path from sequence to purified antibody and binding characterization. More precisely, they deliver full length immunoglobulin G (IgG) with surface plasmon resonance-binding characterization. Purified full length IgG, or single chain, allows researchers to characterize candidates in the format intended to advance. Twist says this reduces the gap between early binding data and downstream development. Antibodies with a Twist. Taking a wider view, this workflow incorporates cell-free protein expression powered by LenioBio's ALiCE eukaryotic expression system. This is optimized for rapid production of full length IgGs and recombinant proteins. Customer-defined variable region sequences can be turned around into a number of formats. Purified antibodies, available from 5 to 20 μg, can directly route into SPR binding characterization. Turnaround time begins at just five days. Twist CEO and Co-Founder Emily Leproust, PhD, believes turning a growing range of candidates into experimental data is critical. "Twist Express Screening Antibodies bring speed and scalability to early-stage characterization," Leproust said. "This enables researchers to move broader candidate sets from sequence to data, iterate faster, and focus resources on greatest potential." Twist Bioscience is a mid-cap growth and value biotech company. The company says that Twist Express Screening Antibodies boost its broader characterization portfolio. Also recently, Twist joined with Lilly TuneLab on antibody drug discovery. Meanwhile, LenioBio and Twist announced a collaboration on AI drug discovery models in May 2026. "AI-led antibody development is one of the most exciting growth areas," Leproust said at the time. Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Twist Bioscience (NASDAQ:TWST) shares climb 10.5% - should you Buy? Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) shot up 10.5% on Tuesday. The company traded as high as $159.31 and last traded at $160.4610. 915,491 shares traded hands during mid-day trading, a decline of 47% from the average session volume of 1,730,415 shares. The stock had previously closed at $145.25. Analyst upgrades and downgrades. A number of analysts recently commented on the company. UBS Group initiated coverage on Twist Bioscience in a research note on Wednesday, September 9th. They set a "neutral" rating and a $144.00 price objective on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research note on Monday, September 21st. Leerink Partners upped their target price on shares of Twist Bioscience from $160.00 to $190.00 and gave the company an "outperform" rating in a report on Tuesday, September 29th. Barclays raised their price target on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 7th. Finally, BWS Financial reiterated a "sell" rating and set a $45.00 price target on shares of Twist Bioscience in a report on Friday, September 18th. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $143.67. Twist Bioscience price performance. The company has a market capitalization of $10.03 billion, a price-to-earnings ratio of -72.06 and a beta of 2.19. The company has a fifty day simple moving average of $150.30 and a two-hundred day simple moving average of $86.26. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The business had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. During the same quarter last year, the business earned $0.33 EPS. Twist Bioscience's revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year. Insiders place their bets. In other Twist Bioscience news, insider Dennis Cho sold 9,514 shares of the firm's stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,797,004.32. Following the sale, the insider directly owned 63,789 shares of the company's stock, valued at approximately $12,048,466.32. This trade represents a 12.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 356,546 shares of the firm's stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $157.99, for a total value of $56,330,702.54. Following the completion of the sale, the chief executive officer directly owned 620,589 shares in the company, valued at approximately $98,046,856.11. The trade was a 36.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 601,920 shares of company stock valued at $93,768,202. 3.08% of the stock is owned by corporate insiders. Institutional investors weigh in on Twist Bioscience. Several hedge funds have recently modified their holdings of the stock. Root Financial Partners LLC purchased a new stake in Twist Bioscience in the third quarter valued at approximately $33,000. Signaturefd LLC raised its stake in Twist Bioscience by 94.3% during the third quarter. Signaturefd LLC now owns 548 shares of the company's stock worth $106,000 after purchasing an additional 266 shares during the period. Allworth Financial LP purchased a new position in Twist Bioscience during the second quarter worth approximately $62,000. Trifecta Capital Advisors LLC purchased a new position in Twist Bioscience during the second quarter worth approximately $63,000. Finally, Western Wealth Management LLC acquired a new position in shares of Twist Bioscience in the 1st quarter valued at $31,000. About Twist Bioscience. Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research. Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products. Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.